Cargando…

Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease

OBJECTIVE: To determine the risk of hip fracture in persons with Alzheimer´s disease (AD) who initiated antiepileptic drugs (AEDs). METHODS: In the Medication use and AD (MEDALZ) cohort of 70,719 Finnish community dwellers with clinically verified incident AD diagnosis in 2005–2011, we identified al...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisa, Federica, Reinold, Jonas, Lavikainen, Piia, Koponen, Marjaana, Taipale, Heidi, Tanskanen, Antti, Tiihonen, Jari, Hartikainen, Sirpa, Tolppanen, Anna-Maija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075175/
https://www.ncbi.nlm.nih.gov/pubmed/33911901
http://dx.doi.org/10.2147/CLEP.S278306
_version_ 1783684490165485568
author Pisa, Federica
Reinold, Jonas
Lavikainen, Piia
Koponen, Marjaana
Taipale, Heidi
Tanskanen, Antti
Tiihonen, Jari
Hartikainen, Sirpa
Tolppanen, Anna-Maija
author_facet Pisa, Federica
Reinold, Jonas
Lavikainen, Piia
Koponen, Marjaana
Taipale, Heidi
Tanskanen, Antti
Tiihonen, Jari
Hartikainen, Sirpa
Tolppanen, Anna-Maija
author_sort Pisa, Federica
collection PubMed
description OBJECTIVE: To determine the risk of hip fracture in persons with Alzheimer´s disease (AD) who initiated antiepileptic drugs (AEDs). METHODS: In the Medication use and AD (MEDALZ) cohort of 70,719 Finnish community dwellers with clinically verified incident AD diagnosis in 2005–2011, we identified all incident users of AEDs using national Prescription register. AEDs were classified as older (valproate, carbamazepine, clonazepam, phenytoin, levetiracetam, primidone) or newer (pregabalin, gabapentin, oxcarbazepine, lamotrigine, topiramate). We matched each user to 2 non-users. Incident hip fractures until 2015 were identified from the Care register for health care. We calculated inverse probability of treatment weighted hazard ratios (HR), with 95% confidence intervals, using Cox regression. RESULTS: Altogether 5522 incident users were identified and matched to 11,044 non-users (in both groups, women: 65%; median age: 81 years). Altogether 53.3% of users initiated with newer AEDs (pregabalin 79.8%, gabapentin 10.2%) while 46.7% initiated with older AEDs (valproate 67.6%, carbamazepine 13.0%). Age- and sex-adjusted IR of hip fracture per 100 person-years was 1.8 (95% CI 1.6–1.9) in non-users and 2.0 (95% CI 1.8–2.2) in users. Increased risk of hip fracture was observed in users (HR 1.17, 95% CI 1.05–1.30) compared with non-users. The risk was higher for short duration of use (<14 weeks, HR 3.64, 95% CI 2.90–4.58) than for medium duration (14 to <64 weeks, HR 1.74, 95% CI 1.48–2.05) or ≥64 weeks’ use (HR 1.23, 95% CI 1.08–1.40), compared to non-users with same follow-up time. Older AEDs had HR of 1.46 (1.03–2.08) compared with newer AEDs. CONCLUSION: Our results imply that AED use is associated with an increased risk of hip fracture in people with AD. These findings prompt careful consideration before prescribing AEDs to persons with AD. Persons with AD treated with antiepileptics should be carefully monitored due to their increased risk of falling and fractures.
format Online
Article
Text
id pubmed-8075175
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80751752021-04-27 Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease Pisa, Federica Reinold, Jonas Lavikainen, Piia Koponen, Marjaana Taipale, Heidi Tanskanen, Antti Tiihonen, Jari Hartikainen, Sirpa Tolppanen, Anna-Maija Clin Epidemiol Original Research OBJECTIVE: To determine the risk of hip fracture in persons with Alzheimer´s disease (AD) who initiated antiepileptic drugs (AEDs). METHODS: In the Medication use and AD (MEDALZ) cohort of 70,719 Finnish community dwellers with clinically verified incident AD diagnosis in 2005–2011, we identified all incident users of AEDs using national Prescription register. AEDs were classified as older (valproate, carbamazepine, clonazepam, phenytoin, levetiracetam, primidone) or newer (pregabalin, gabapentin, oxcarbazepine, lamotrigine, topiramate). We matched each user to 2 non-users. Incident hip fractures until 2015 were identified from the Care register for health care. We calculated inverse probability of treatment weighted hazard ratios (HR), with 95% confidence intervals, using Cox regression. RESULTS: Altogether 5522 incident users were identified and matched to 11,044 non-users (in both groups, women: 65%; median age: 81 years). Altogether 53.3% of users initiated with newer AEDs (pregabalin 79.8%, gabapentin 10.2%) while 46.7% initiated with older AEDs (valproate 67.6%, carbamazepine 13.0%). Age- and sex-adjusted IR of hip fracture per 100 person-years was 1.8 (95% CI 1.6–1.9) in non-users and 2.0 (95% CI 1.8–2.2) in users. Increased risk of hip fracture was observed in users (HR 1.17, 95% CI 1.05–1.30) compared with non-users. The risk was higher for short duration of use (<14 weeks, HR 3.64, 95% CI 2.90–4.58) than for medium duration (14 to <64 weeks, HR 1.74, 95% CI 1.48–2.05) or ≥64 weeks’ use (HR 1.23, 95% CI 1.08–1.40), compared to non-users with same follow-up time. Older AEDs had HR of 1.46 (1.03–2.08) compared with newer AEDs. CONCLUSION: Our results imply that AED use is associated with an increased risk of hip fracture in people with AD. These findings prompt careful consideration before prescribing AEDs to persons with AD. Persons with AD treated with antiepileptics should be carefully monitored due to their increased risk of falling and fractures. Dove 2021-04-22 /pmc/articles/PMC8075175/ /pubmed/33911901 http://dx.doi.org/10.2147/CLEP.S278306 Text en © 2021 Pisa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pisa, Federica
Reinold, Jonas
Lavikainen, Piia
Koponen, Marjaana
Taipale, Heidi
Tanskanen, Antti
Tiihonen, Jari
Hartikainen, Sirpa
Tolppanen, Anna-Maija
Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title_full Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title_fullStr Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title_full_unstemmed Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title_short Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
title_sort hip fracture risk in antiepileptic drug initiators and non-initiators with alzheimer’s disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075175/
https://www.ncbi.nlm.nih.gov/pubmed/33911901
http://dx.doi.org/10.2147/CLEP.S278306
work_keys_str_mv AT pisafederica hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT reinoldjonas hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT lavikainenpiia hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT koponenmarjaana hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT taipaleheidi hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT tanskanenantti hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT tiihonenjari hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT hartikainensirpa hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease
AT tolppanenannamaija hipfractureriskinantiepilepticdruginitiatorsandnoninitiatorswithalzheimersdisease